CASRAI Dictionary

Tag: ai in research administration

  • NIH Grant Types: R01, R21, K and T32 Compared

    NIH grant types are distinguished by a system of three-character activity codes — R01, R21, K and T32 are four of the most common — that signal a proposal’s scope, funding ceiling, career stage and duration before a reviewer reads a single word of the research plan. An R01 funds a mature, hypothesis-driven research project for independent investigators; an R21 funds early-stage, high-risk exploratory work with no preliminary-data requirement; a K award funds mentored career development for researchers moving toward independence; and a T32 funds an institution’s structured training programme for pre- and postdoctoral trainees, not an individual investigator’s project.

    An NIH activity code is a three-character designator — such as R01 or K08 — that the National Institutes of Health assigns to a grant mechanism to indicate the research or training activity it supports, as defined in NIH’s own Activity Codes reference. For administrators onboarding a new PI or trainee, matching the right code to career stage and project maturity is the single most consequential early decision in the proposal process.

    What Are NIH Grant Activity Codes?

    NIH uses activity codes to differentiate the wide variety of research-related programmes it funds, rather than a single generic “grant” category. Codes are grouped into families: R-series research grants, K-series career development awards, T- and F-series training and fellowship awards, P-series programme and centre grants, and U-series cooperative agreements.

    A separate, frequently confused numbering system covers application type — Type 1 (new), Type 2 (competing renewal), Type 3 (administrative supplement), Type 4 (competing extension, limited to MERIT and SBIR Fast-Track awards) and Type 5 (non-competing continuation). These numeric types describe an application’s relationship to a prior award, not the activity code itself — confusing the two is a common onboarding error.

    • R-series — discrete research projects (R01, R21, R03, R43/R44 for SBIR).
    • K-series — mentored or independent career development (K01, K08, K23, K99/R00).
    • T- and F-series — institutional training grants and individual fellowships.
    • P- and U-series — multi-project centres and cooperative agreements.

    SBIR applicants encounter a parallel track: R43 (Phase I feasibility) and R44 (Phase II full research and development) fund the SBIR NIH grant pathway for for-profit small businesses, under NIH’s federally mandated small-business set-aside.

    R01 vs R21: Which Mechanism Fits Your Project Stage?

    The R01 is NIH’s oldest and most widely used grant mechanism, built to support a specified, hypothesis-driven research project with a well-developed plan and substantial preliminary data. It is investigator-initiated: the researcher, not NIH, defines the scientific question and approach.

    The R21 exists for the opposite situation — an idea too early or high-risk for an R01. It funds exploratory work, including novel techniques or conceptually innovative approaches, without requiring extensive preliminary data.

    • R01: typically 3–5 years of support; no fixed budget ceiling, but requests above $500,000 in direct costs in any year require prior NIH approval; competitively renewable.
    • R21: capped at 2 years; combined direct costs limited to $275,000 for the full project period, with no more than $200,000 in any single year; not renewable.

    Administrators guiding a new PI should treat the R21’s lower ceiling and shorter clock as deliberate design, not a lesser award — it exists to de-risk ideas before they are mature enough for R01-scale commitment.

    What Do K Awards Fund, and Who Qualifies?

    A K award — the NIH Career Development Award series — funds protected research time and structured mentorship for investigators transitioning toward independence, rather than funding a discrete project on its own merits. Eligible applicants range from postdoctoral and clinical fellows to early-career faculty, depending on the specific K mechanism.

    Mentored variants (K01, K08 for clinician-scientists, K23 for patient-oriented researchers) require a named mentor and a formal career plan alongside the research strategy. The K99/R00 “Pathway to Independence” award is structured differently: a mentored K99 phase transitions automatically into an independent R00 phase once the recipient secures a faculty position.

    K awardees typically commit a minimum of 9 person-months, i.e. 75% full-time professional effort, to the funded activities — a requirement institutions must factor into faculty workload planning before submission, not after award.

    What Is a T32, and How Does Institutional Training Funding Work?

    A T32 is fundamentally different: it is awarded to an institution, not an individual. Formally a Ruth L. Kirschstein National Research Service Award (NRSA) institutional training grant, a T32 funds a structured programme through which the institution recruits, appoints and mentors pre- and postdoctoral trainees.

    The institution’s programme director designs the curriculum, selects appointees internally, and reports outcomes to NIH; trainees do not apply to NIH directly. T32-supported trainees must generally be U.S. citizens, non-citizen nationals, or permanent residents at appointment — an eligibility restriction that does not apply uniformly across R- and K-series awards.

    Because T32 support flows through the institution, administrators — not the trainee — are usually responsible for appointment paperwork, stipend administration and NIH’s annual training-grant progress reporting.

    Quick-Reference Comparison Table

    The table below summarises the four core mechanisms plus the SBIR track, for administrators triaging which code fits a given PI or trainee.

    Code Primary purpose Typical applicant Duration Funding ceiling Renewable
    R01 Discrete, hypothesis-driven research project Independent investigator 3–5 years No fixed cap; >$500,000/year needs prior approval Yes, competitively
    R21 Exploratory, high-risk/high-reward research Early-stage or established investigator with a novel idea Up to 2 years $275,000 total direct costs No
    K award Mentored career development toward independence Postdoctoral fellow or junior faculty Up to 5 years Salary plus research support; institution-negotiated Generally no
    T32 Institutional pre-/postdoctoral training programme Institution (on behalf of trainees) Long-term, competitively renewed Stipends, tuition and training-related costs for multiple trainees Yes, competitively
    R43/R44 (SBIR) Small-business feasibility (R43) and full R&D (R44) For-profit small business Phase I ~6–12 months; Phase II ~2 years Set by SBIR budget guidelines per topic Phase II follows Phase I

    Answer-First Q&A

    What Are the Levels of NIH Grants?

    NIH grants are grouped into major series rather than a single hierarchy of “levels”: Research Grants (R series, including R01 and R21), Career Development Awards (K series), Research Training and Fellowships (T and F series), and Programme Project/Centre Grants (P and U series), each serving a distinct career stage or project scale.

    What Is a Type 3 NIH Grant?

    A Type 3 designation is not an activity code but an application type: an administrative supplement requesting additional funds during a current project period, usually to cover unforeseen costs. The added work must stay within the originally approved scope and cannot extend beyond the current award’s end date.

    What Is a Type 4 Grant?

    A Type 4 is a competing extension application, providing additional time and funds beyond an award’s originally recommended level. NIH restricts Type 4 applications to specific mechanisms — notably MERIT awards and SBIR Fast-Track projects — rather than making them available across all activity codes.

    What This Means for Research Administrators

    Mechanism choice drives everything downstream: budget justification format, biosketch and other-support requirements, and the compliance calendar an office must track. A T32 appointment triggers citizenship-eligibility checks that an R01 never requires; a K award’s effort commitment must be reconciled against base-salary policy before submission, not after award.

    When onboarding a new PI or trainee, administrators should map career stage and project maturity to mechanism before drafting begins, since NIH’s forms, page limits and required attachments differ by activity code. Many NIH grant proposal template resources circulating online are institution-specific rather than NIH-issued; the authoritative source for current forms remains grants.nih.gov.

    This mechanism-mapping discipline sits alongside the broader workload covered under research administration practice — proposal development is one stage in a longer sponsored-project lifecycle.

    Choosing the Right Mechanism

    There is no universally “best” NIH grant type — only the mechanism matching a researcher’s career stage and a project’s maturity. A trainee belongs under a T32 or fellowship, not an R01; an untested idea belongs under an R21, not a premature R01 submission; a faculty member building independence belongs under a K award before, not instead of, their first R01.

    As NIH’s activity-code system evolves, research administration offices that maintain a current, institution-specific decoder for their most-used codes will save new PIs and trainees the costliest early-career mistake: applying to the wrong mechanism entirely.

  • Research Integrity Office: A Governance Model

    A well-governed research integrity office reports to a senior academic officer independent of Human Resources, draws its investigation panels from cross-disciplinary senior staff plus at least one external member, and keeps case-handling separate from disciplinary sanctioning — a structure distinct from simply appointing a named Research Integrity Officer.

    A research integrity office is the standing institutional unit responsible for policy, training oversight and the inquiry-and-investigation process for allegations of research misconduct — distinct from the individually appointed Research Integrity Officer who runs its day-to-day casework.

    What Is a Research Integrity Office?

    A research integrity office is the standing unit — not a single job title — that owns an institution’s policy on responsible conduct of research, coordinates training, and runs the formal process when misconduct is alleged. Most coverage of this topic focuses on the individual Research Integrity Officer (RIO) career pathway; far less has been written about how the surrounding office should be structured as a governance function.

    The office typically sits alongside, but separate from, two adjacent functions: the research ethics committee, which reviews prospective study design and participant safeguards before research starts, and the research governance office, which manages sponsor, funder and regulatory compliance (common in clinical and health research). Conflating the three creates confusion about who owns what when a concern is first raised.

    It is also worth distinguishing an institution’s own office from the UK Research Integrity Office (UKRIO), an independent charity established in 2006 that provides advisory support — including case advice and training — to around 160 subscribing UK research organisations. UKRIO is a sector-wide advisory body; it does not replace the internal office each institution is expected to run under the Concordat to Support Research Integrity.

    Where Should the Office Report? Comparing Reporting-Line Models

    The office should report to a senior academic officer — a Pro-Vice-Chancellor for Research, Provost, or Vice-President for Research — never through a line that also manages HR casework or sits inside a single faculty. This gives the office standing to investigate any member of staff, including senior leadership, without a structural conflict of interest. In the United States, 42 CFR Part 93 requires any institution receiving Public Health Service research funding to designate an RIO with documented authority to act independently of the respondent’s own management chain.

    Governance model Reporting line Independence from HR Best fit
    Centralised office Reports directly to Provost / PVC-Research High — own budget line and case files Large, research-intensive universities
    Devolved faculty network Faculty-based integrity advisors report to a central RIO, who reports to the Provost Medium — depends on the advisor’s own line management Multi-faculty institutions with devolved research cultures
    External advisory subscription Advisory only; the institution retains formal decision-making authority High for advice, but not a substitute for a named internal Officer Smaller institutions, or as an escalation and second-opinion route

    King’s College London illustrates the devolved model: its Research Integrity Office is supplemented by faculty-based “Research Integrity Champions and Advisors” who provide local, first-line support while formal casework remains with the central office. Whichever model is chosen, the reporting line — not the job title of the person running it — determines whether the office can act without institutional pressure.

    Who Should Sit on the Investigation Panel?

    An investigation panel needs disciplinary expertise, distance from the respondent’s own department, and — for serious cases — at least one external, cross-institutional member. It should not include a standing HR representative as a voting member, because the panel’s task is to determine whether fabrication, falsification or plagiarism occurred, which is a different test to the workplace-conduct standard HR applies in disciplinary proceedings.

    • Cross-disciplinary membership that avoids conflicts of interest with the respondent’s own department or research group
    • At least one external member drawn from outside the institution for investigation-stage (not preliminary assessment-stage) cases
    • Separated roles across stages: an initial assessor, a fact-finding inquiry panel, and — only where warranted — a formal investigation committee
    • A documented recusal process for declared conflicts of interest
    • An independent secretariat, provided by the research integrity office itself rather than by HR

    Panel members require training on the institution’s misconduct policy and, where applicable, national frameworks such as the UKRIO Code of Practice for Research, which sets out five core principles — honesty, rigour, transparency and open communication, care and respect, and accountability — as the basis on which allegations are assessed.

    Why Independence from HR Is Non-Negotiable

    Independence from HR matters because a misconduct investigation establishes a factual finding about the integrity of the research record — a different exercise to the reasonable-conduct standard HR applies in employment disciplinary proceedings. Conflating the two risks the investigation being challenged as procedurally unfair, or as a pretext for an unrelated employment dispute.

    The two functions are sequential, not parallel. UK institutional codes typically specify that HR-led disciplinary procedures begin only once a research integrity office has confirmed a misconduct finding through its own separate process; King’s College London’s published Code of Good Conduct in Research is a public example of an institution setting out both processes as distinct. Confidentiality is a further reason for separation: misconduct proceedings protect the reputations of complainants, respondents and witnesses alike, and narrowing the circle of people with case access — rather than routing it through a general HR caseload — helps preserve that.

    Frequently Asked Questions

    What Does a Research Integrity Office Do?

    A research integrity office owns institutional policy on responsible research conduct, coordinates training for staff and students, and manages the formal process — assessment, inquiry and, where warranted, investigation — for allegations of research misconduct. It reports outcomes to senior leadership but does not itself impose employment sanctions.

    What Is the UK Research Integrity Office, and How Is It Different from an Institutional Office?

    UKRIO is an independent UK charity, established in 2006, that advises around 160 subscribing institutions and helped develop the Concordat to Support Research Integrity. It is a sector-wide advisory body, not a substitute for the internal office each institution must run to handle its own cases.

    What Are the Five Principles of Research Integrity?

    Under the UKRIO Code of Practice for Research, the five commonly cited principles are honesty, rigour, transparency and open communication, care and respect, and accountability. These principles inform how research integrity offices and panels assess whether an allegation meets the threshold for a formal misconduct finding.

    What Counts as Research Misconduct?

    Research misconduct generally covers fabrication, falsification and plagiarism, alongside proceeding without required ethical approvals and manipulating data, materials or processes to misrepresent results. A research integrity office defines the precise scope in institutional policy, aligned to national frameworks such as the Concordat to Support Research Integrity.

    Implications for Institutions Building or Reforming an Office

    The revised Concordat to Support Research Integrity (2025) sharpens its fifth commitment — accountability and continuous improvement — which puts explicit pressure on institutions to evidence, not merely assert, that their office structure is independent in practice. Institutions still relying on an RIO who reports through a research-office middle layer, or panels that include HR as a standing member, should treat this as a governance gap to close rather than an administrative preference.

    The wider research administration function increasingly treats research integrity governance as core infrastructure rather than a compliance afterthought, alongside ethics review and research governance offices. As AI-assisted data analysis and image manipulation raise new detection challenges, panels with genuine cross-disciplinary and external representation — reporting through a line insulated from both departmental and HR pressure — will be better placed to investigate credibly and defend their findings if challenged.

  • Questionable Research Practices vs Misconduct: Where Institutions Draw the Line

    Questionable research practices (QRPs) are not research misconduct, and treating them as identical is where institutional triage goes wrong. Misconduct — fabrication, falsification, and plagiarism (FFP) — requires intent and a formal proof standard; QRPs such as p-hacking, HARKing, and selective reporting occupy a wider grey zone that most institutions route through a separate, lower-intensity process.

    A questionable research practice is a research or reporting behaviour that deviates from rigorous methodological or ethical norms without meeting the legal definition of fabrication, falsification, or plagiarism. The distinction matters because it determines which procedural track — and which evidentiary burden — an institution applies to a complaint.

    What counts as a questionable research practice?

    QRPs cluster around the design, analysis, and reporting stages of a study. The most cited taxonomy comes from an incentivised self-report survey published in Psychological Science (John, Loewenstein & Prelec, 2012), which found admission rates for practices such as selectively reporting studies “that worked” approaching 50% — far higher than admitted rates of outright data fabrication, which stayed under 2%. That gap is itself the argument for treating QRPs as a distinct governance problem rather than a rare edge case of misconduct.

    • P-hacking (data dredging): running multiple analyses or exclusion criteria until a result reaches statistical significance, then reporting only that version.
    • HARKing: presenting a post hoc, exploratory finding as though it were the pre-specified hypothesis.
    • Selective/cherry-picked reporting: omitting non-significant outcomes, conditions, or measures from the published record.
    • Salami slicing: splitting one dataset into the minimum publishable units to inflate output count.
    • Honorary or ghost authorship: crediting non-contributors or omitting contributors, which is why standardised contributor role disclosure matters for accountability.
    • Inadequate data retention: failing to keep raw data, code, or protocols available for verification.

    How do QRPs differ from research misconduct?

    Under US federal policy (42 CFR Part 93, administered by the Office of Research Integrity), research misconduct is defined narrowly as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting results. Three conditions must all be met: a significant departure from accepted practices, intentional/knowing/reckless conduct, and proof by a preponderance of the evidence. The same regulation explicitly excludes “honest error” and “differences of opinion” from the misconduct definition — which is precisely the space most QRPs occupy.

    UK guidance frames the same boundary differently but reaches a similar conclusion. UKRIO’s 2023 guidance by Simon Kolstoe, “Defining the Spectrum of Questionable Research Practices,” describes a continuum running from honest error and sloppiness through to QRPs and, at the far end, fabrication, falsification, and criminality — with no single fixed cut-off point.

    Dimension Questionable research practice Research misconduct (FFP)
    Intent required Not required — may be unintentional, driven by pressure or ignorance Must be intentional, knowing, or reckless
    Governing definition No single legal definition; institutional/disciplinary norms 42 CFR Part 93 (US); institutional misconduct policy (UK/EU)
    Standard of proof Not applicable — assessed for pattern/severity, not adjudicated Preponderance of the evidence
    Typical examples P-hacking, HARKing, selective reporting, salami slicing Fabricated data, altered images, verbatim plagiarism
    Usual institutional track Research governance, retraining, correction, departmental review Formal inquiry and investigation with findings and sanctions

    How do institutions triage an allegation?

    Under the ORI model that most US research institutions adopt, and which UK bodies broadly mirror in structure, a complaint moves through staged gates rather than a single up-or-down decision.

    1. Assessment: a Research Integrity Officer performs an initial review to establish whether, if the allegation were true, it would meet the FFP definition and falls within the institution’s jurisdiction. Concerns that describe sloppiness, honest error, or a QRP without evidence of intent are typically redirected here rather than escalated.
    2. Inquiry: a limited fact-finding step, conducted under 42 CFR Part 93 within 60 calendar days unless circumstances clearly warrant longer, to decide whether a full investigation is warranted.
    3. Investigation: a formal, evidence-gathering process triggered only once the inquiry finds a sufficient basis, applying the preponderance-of-evidence standard and producing a written report with findings.

    QRPs that do not clear the assessment gate are not dismissed outright — the National Academies of Sciences, Engineering, and Medicine’s 2017 report Fostering Integrity in Research proposed the term “detrimental research practices” specifically to argue that institutions need a formal, non-misconduct track for exactly this category, rather than either ignoring it or misapplying the misconduct process to it. COPE’s flowcharts for publishers follow the same logic: suspected fabrication routes to a formal investigation referral, while methodological concerns typically route to correction or expression-of-concern mechanisms first.

    Why does the distinction change institutional response?

    Misapplying the misconduct process to a QRP over-penalises ambiguous conduct and consumes scarce Research Integrity Officer capacity on cases that cannot meet the intent standard. Under-applying it — treating a concealed fabrication as “just” a QRP — lets a genuine breach evade the preponderance-of-evidence process entirely. Accurate triage at the assessment stage is therefore the single highest-leverage decision point in the entire allegation-handling pipeline, and it depends on evaluators being able to name the difference precisely rather than treating “research integrity concern” as one undifferentiated category.

    This is also why standardised terminology for research integrity concepts, and consistent research administration processes for logging and routing complaints, reduce inconsistent outcomes across departments within the same institution.

    Answer-first questions on QRPs and misconduct

    What is the difference between questionable research practices and research misconduct?

    Research misconduct is fabrication, falsification, or plagiarism committed intentionally, knowingly, or recklessly and proven by a preponderance of evidence under frameworks such as 42 CFR Part 93. QRPs are a broader, less severe category — practices like p-hacking or HARKing — that may be unintentional and do not meet the FFP definition.

    What are examples of questionable research practices?

    Common QRPs include p-hacking, HARKing, selective or cherry-picked reporting, salami slicing of datasets into multiple papers, inadequate record-keeping, and honorary or ghost authorship. None of these automatically constitutes misconduct unless deliberate concealment or fabrication can be demonstrated.

    Is p-hacking considered research misconduct?

    Generally no. P-hacking is classified as a questionable research practice because it typically reflects flawed analytical judgement or incentive pressure rather than deliberate fabrication. It can escalate to misconduct only if a researcher knowingly falsifies or conceals the analytic process to deceive reviewers.

    Who decides whether an allegation is misconduct or a questionable practice?

    A Research Integrity Officer (or institutional equivalent) makes this call at the assessment and inquiry stages, evaluating whether alleged conduct could meet the FFP definition before any formal investigation begins. This gatekeeping decision determines which procedural track and evidentiary standard apply.

    Where institutional policy is heading

    Recent scholarship — including a 2026 classification study in a leading research-ethics journal — continues to push toward more granular, ranked taxonomies of QRPs rather than a single undifferentiated label, reflecting growing recognition that “questionable research practice” spans behaviours of very different severity. For institutions, the practical implication is unchanged: allegation-handling policies need an explicit, documented triage step that distinguishes FFP-eligible conduct from the wider QRP category before any case enters a formal investigation track. Institutions that skip this step either over-invest in low-severity concerns or under-investigate the ones that matter.

  • REF Impact Case Study: Evidence for REF 2029

    A REF impact case study is a structured, evidence-backed narrative — capped at 2,200 words under REF 2029 rules — that links a submitting unit’s research to a verifiable benefit beyond academia. Research offices build the underlying evidence base years in advance, because the case study is only as strong as the corroborating sources, testimonials and documentary trail collected while the impact is happening, not reconstructed after the fact.

    A REF impact case study is defined by Research England as a submission describing “an effect on, change or benefit to the economy, society, culture, public policy or services, health, the environment or quality of life, beyond academia” that occurred during the eligible assessment window.

    What is a REF impact case study, structurally?

    A REF impact case study (ICS) is one of the fixed-format submissions that make up the Engagement and Impact (E&I) element of the Research Excellence Framework. Under REF 2029 guidance published by Research England on 10 December 2025, engagement and impact accounts for 25% of a submitting unit’s overall REF score — up from 20% under REF 2014’s original impact weighting.

    Each ICS follows the same template Research England used for REF 2021: a summary of the impact, an account of the underpinning research, a details-of-impact narrative, a references list, and a list of corroborating sources. Panels assess every case study against two criteria only — reach (the extent and diversity of beneficiaries) and significance (the degree of benefit conferred) — regardless of whether the impact occurred locally or internationally.

    The underpinning-research link is the single most scrutinised element of an ICS. REF 2029 guidance defines “underpinned by” as meaning the research “made a distinct and material contribution to the impact taking place, such that the impact would not have occurred or would have been significantly reduced without the contribution of that research.” Panels grade an ICS unclassified if this link cannot be demonstrated.

    Research offices evidence the link with:

    • Up to six references to specific research outputs, which may include any output type in the REF output glossary — not just journal articles.
    • An explicit account of how the research was disseminated, exploited or taken up by users or beneficiaries.
    • Confirmation that the underpinning research was produced by staff working in the submitting unit at the relevant time, even if those staff have since left the institution.

    Notably, REF 2029 has removed the requirement that underpinning research meet a 2* quality threshold — research now only needs to meet the general REF definition of research, which widens the pool of eligible work that can anchor a case study.

    What evidence standards does REF 2029 require?

    Corroborating evidence exists to verify the claims made in the narrative, not to substitute for them. REF 2029 guidance caps this section at a maximum of 10 sources, of which no more than five may be named individuals who could be contacted to confirm a claim. Sources must be external to the submitting institution and must state, explicitly, which claim in the case study each one corroborates.

    Accepted evidence types include published reports, web links used solely for verification, confidential documents, and factual statements already supplied to the institution by users or beneficiaries. Research England has stated that panels will not follow URLs to gather additional supporting information beyond what is cited — evidence has to stand on its own within the submitted material.

    REF cycle Impact/E&I weighting Underpinning research quality bar Substantive-text word limit
    REF 2014 20% 2* threshold applied ~4 pages (no fixed word cap)
    REF 2021 25% 2* threshold applied ~4–5 pages (no fixed word cap)
    REF 2029 25% 2* threshold removed 2,200-word hard maximum

    What are the REF 2029 thresholds — and the common template pitfalls?

    The number of case studies a unit must submit is set by its volume measure in full-time-equivalent (FTE) staff, not by discretion. Research England’s REF 2029 Section 6 guidance sets out the following bands:

    Volume measure (FTE) Number of ICS required
    Up to 9.99 (option 1) 1
    Up to 9.99 (option 2) 2
    10 to 19.99 2
    20 to 39.99 3
    40 to 59.99 4
    60 to 89.99 5
    90 to 119.99 6
    120 to 169.99 7
    170 or more 8, plus one further ICS per additional 50 FTE

    Submitting fewer than the required number is not permitted without penalty: any missing case study is automatically graded unclassified, which drags down the whole impact sub-profile. The most common template pitfalls research offices report are:

    • Treating the suggested 100/600/1,500-word split across summary, underpinning research and details-of-impact sections as a rigid quota rather than a guide — the 2,200-word figure is a hard ceiling across all three, not per section.
    • Submitting an ICS whose underpinning research falls outside the eligible production window (1 January 2008 to 31 December 2028 for REF 2029) or whose claimed impact falls outside the eligible impact window (1 August 2020 to 31 July 2028).
    • Failing to distinguish a genuinely “continuing” case study from a new one — Research England treats an ICS as continuing only if both the underpinning research and the impact type/beneficiaries substantially overlap with a REF 2014 or REF 2021 submission.
    • Relying on testimonial evidence that does not name which specific claim it corroborates, which auditors and panels are instructed to discount.

    Answer-first questions research offices ask

    How much is a REF impact case study worth?

    Impact case studies are not scored in cash terms directly, but funding follows the REF results. Writing in 2023 for Research Professional, higher education analyst Simon Kerridge estimated that a single 4* impact case study from a very large unit of assessment could be worth over £2 million in funding allocation across a REF cycle, as cited by the LSE Impact of Social Sciences blog.

    How many impact case studies are required for REF 2029?

    The number scales with a unit’s volume measure in FTE staff, from one or two case studies for units under 10 FTE up to eight or more for units of 170+ FTE, plus one additional case study per further 50 FTE. Submitting below the required number results in an automatic unclassified grade for each missing case study.

    How do you write a REF impact case study?

    A compliant ICS follows the fixed template: a short summary of the impact, an account of the underpinning research with up to six output references, and a details-of-impact narrative explaining how the research led to the benefit, who benefited, and by how much — supported by up to 10 external corroborating sources, all within a 2,200-word hard limit.

    Does the REF assess impact directly, or only through case studies?

    The REF assesses impact exclusively through the submitted case studies and the accompanying strategy, people and research environment (SPRE) statement — it does not independently audit an institution’s broader societal footprint. Panels judge only the reach and significance evidenced within the submitted ICS documents themselves.

    What this means for research office workflow

    Because corroborating evidence must be collected contemporaneously to survive audit, research administration teams increasingly run impact tracking as a continuous process, not a pre-deadline scramble. That means logging engagement activity, securing dated testimonials, and tagging outputs to funders’ ROR and ORCID identifiers, since REF 2029’s additional data fields for funded research — grant number, funder, amount in GBP, formal partners — must be captured at source, not reconstructed later.

    This shifts case-study development from a late-cycle writing exercise to ongoing portfolio management: horizon-scanning which groups have plausible non-academic reach, briefing academics on admissible corroboration, and stress-testing drafts against the “distinct and material contribution” bar before submission.

    Outlook: preparing before the submission window opens

    REF 2029’s guidance modules are still being finalised through 2026, with sub-panel criteria expected to add further detail on how engagement activity and responsible research practices will be recognised within the existing template. Institutions that treat evidence-gathering as infrastructure — built into research administration workflows from the point a grant is awarded — will have a materially easier path to a compliant, well-evidenced case study than those that begin drafting only once the submission system opens.

  • UK Policy Framework for Health and Social Care Research: A Governance Primer

    What Is the UK Policy Framework for Health and Social Care Research?

    The UK Policy Framework for Health and Social Care Research is the single set of standards that governs how health and social care research is designed, sponsored, approved, and reported across England, Northern Ireland, Scotland, and Wales. It was published by the Health Research Authority (HRA) and the four UK health departments in October 2017, replacing the separate national Research Governance Frameworks that each country had previously maintained since the early 2000s.

    For research administrators, the practical significance is that a single rulebook now applies wherever the study touches NHS or Health and Social Care (HSC) patients, service users, data, or tissue — regardless of whether the funder is a UK research council, a charity, a university, or a life sciences company. Any study that falls within scope requires a designated sponsor, appropriate ethical and regulatory approval, and proportionate ongoing oversight before, during, and after delivery.

    The 19 Principles: Structure and Scope

    The framework is built around 19 principles of good practice, split into two tiers. The first 15 apply to all health and social care research; the final four apply only to interventional research, where treatment, care, or service delivery is changed for research purposes.

    • Principles 1–15 (all research): Safety, Competence, Scientific and Ethical Conduct, Patient/Service User/Public Involvement, Integrity/Quality/Transparency, Protocol, Legality, Benefits and Risks, Approval, Information about the Research, Accessible Findings, Choice, Insurance and Indemnity, Respect for Privacy, and Compliance.
    • Principles 16–19 (interventional research only): Justified Intervention, Ongoing Provision of Treatment, Integrity of the Care Record, and Duty of Care.

    Principle 9 (Approval) and Principle 10 (Information about the Research) are the two most operationally significant for grant-funded studies: no study may start until it has a favourable Research Ethics Committee (REC) opinion where required, and every study — bar limited waivers — must be registered publicly before recruitment begins to avoid research waste.

    Every study in scope must have a sponsor: the individual, organisation, or partnership that takes overall responsibility for proportionate, effective arrangements to set up, run, and report the research. For non-commercial, grant-funded studies the sponsor is normally the employer of the chief investigator; for commercial studies it is normally the funder. Crucially, an employer or funder does not become the sponsor automatically — the role must be explicitly accepted and documented.

    Under the framework, the sponsor’s overall responsibility includes:

    1. Identifying and addressing poorly designed research and ensuring proposals are scientifically sound, safe, ethical, legal, and feasible for the duration of the study.
    2. Satisfying itself that investigators, the research team, and research sites are suitable.
    3. Documenting agreed roles, responsibilities, and any delegation of sponsor tasks.
    4. Ensuring adequate insurance or indemnity is in place to cover liabilities arising from the research.
    5. Ensuring public registration before the study starts and accessible reporting of data, tissue, and findings afterwards.
    6. Confirming REC and any other required regulatory approvals are secured before the research begins.
    7. Maintaining adequate finance, risk management, and data management arrangements throughout delivery.
    8. Keeping effective monitoring, progress-reporting, and safety-reporting procedures in place.

    Sponsors of clinical trials of investigational medicinal products (CTIMPs) carry additional statutory duties under the Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031, as amended). Universities and colleges are expected to accept the sponsor role for educational research conducted by their own students, unless the student’s NHS or social care employer prefers to take it on.

    REC Review and NHS/HRA Approval

    Research Ethics Committee review is the framework’s central quality gate. No study may start unless a REC — and, where applicable, another approval body such as the Medicines and Healthcare products Regulatory Agency (MHRA), the Human Fertilisation and Embryology Authority (HFEA), or the Administration of Radioactive Substances Advisory Committee (ARSAC) — has issued a favourable opinion on the protocol and supporting documentation.

    In England, REC review is bundled with the confirmation of capacity and capability at NHS organisations through the HRA Approval process, which replaced separate local Research and Development (R&D) sign-off across NHS trusts in 2016. Applications are submitted and tracked through the Integrated Research Application System (IRAS). This single-approval model is one of the framework’s clearest efficiency gains over the pre-2017 regime, in which sponsors could face duplicated ethics and governance review at every participating site.

    The following table summarises the approval routes that sit alongside REC review, depending on study type.

    Study type Additional approval body Legal basis
    Clinical trials of investigational medicinal products (CTIMPs) MHRA Medicines for Human Use (Clinical Trials) Regulations 2004
    Studies using ionising radiation ARSAC Ionising Radiation (Medical Exposure) Regulations
    Research involving human embryos or gametes HFEA Human Fertilisation and Embryology Act 1990
    Research using confidential patient information without consent Confidentiality Advisory Group (CAG) Health Service (Control of Patient Information) Regulations 2002

    Governance Across the Four UK Nations

    Because health and social care are devolved matters, the framework is implemented by a different lead body in each nation, though the 19 principles and sponsor duties remain constant UK-wide.

    • England: Health Research Authority (HRA) — covers health and adult social care research.
    • Northern Ireland: Department of Health (Northern Ireland) — covers health and social care.
    • Scotland: Scottish Government Health and Social Care Directorates — covers health and adult social care.
    • Wales: Department for Health, Social Care and Early Years, operationalised through Health and Care Research Wales.

    Underlying legislation also varies by nation. Common UK-wide law includes the Data Protection Act 2018, UK GDPR, and the Human Tissue Act, while instruments such as the Adults with Incapacity (Scotland) Act 2000 and the Mental Capacity Act 2005 (England and Wales) apply only where the relevant nation’s remit covers them — a detail sponsors running multi-nation studies frequently miss.

    Frequently Asked Questions

    What is a policy framework?

    A policy framework is a structured set of principles, standards, and accountabilities that organisations must follow within a defined area of activity. In health and social care research, the UK Policy Framework sets 19 such principles covering safety, ethics, transparency, and sponsor accountability, replacing what were previously separate national governance documents.

    What are the ethical frameworks for health research?

    Health research ethics in the UK draws on established principles — autonomy, beneficence, non-maleficence, and justice — operationalised through REC review under the UK Policy Framework. Principles 3, 4, and 12 of the framework specifically require scientifically sound, ethically conducted studies with informed participant choice.

    What are some policies in health and social care?

    Alongside the UK Policy Framework, relevant policies include data protection and confidentiality rules (UK GDPR, Data Protection Act 2018), safeguarding policies, consent and capacity policies, and organisation-specific research governance procedures that translate the framework’s sponsor and REC approval requirements into local practice.

    What are frameworks in healthcare?

    In healthcare, a framework is a formally published document that sets shared expectations for practice across organisations. The UK Policy Framework for Health and Social Care Research is one such framework: a single, UK-wide reference that sponsors, investigators, and NHS/HSC organisations must follow when managing research involving patients or service users.

    Implications for Research Administrators

    For institutional research offices, the framework’s practical weight falls on three activities: confirming sponsorship arrangements before a grant is accepted, tracking REC and HRA/NHS approval milestones against funder timelines, and maintaining the documentation trail — protocols, risk assessments, monitoring reports — that demonstrates ongoing compliance with the 19 principles.

    Bodies such as the Association of Research Managers and Administrators (ARMA) in the UK, and international counterparts including INORMS and NCURA, treat sponsor-duty literacy as a core competency for research administration staff, precisely because sponsor obligations under this framework sit outside the funder’s own grant terms and conditions — a distinction that is frequently misunderstood by newly grant-funded principal investigators.

    A common failure mode is treating “sponsor” and “funder” as synonymous. They are not: a funder can decline the sponsor role entirely, leaving the chief investigator’s employer to accept it, with all the attendant obligations around insurance, monitoring, and public registration described above.

    What This Means Going Forward

    The UK Policy Framework for Health and Social Care Research remains the definitive reference for governance obligations across NHS and HSC research, and its principle-based, proportionate design has held up well against a decade of regulatory change, including UK GDPR and post-Brexit clinical trials reform. For institutions managing grant-funded clinical or social care studies, the operational priority is unchanged: confirm sponsorship early, sequence REC and NHS approval realistically against funder milestones, and keep documentation aligned to the framework’s principles rather than treating it as a one-off compliance checkbox.

    Research administrators seeking to embed these obligations into wider institutional practice may find it useful to review CASRAI’s broader coverage of research administration standards and terminology in the CASRAI Dictionary.

  • UKRI Policy Fellowships 2026: Embedding Researchers in Government

    What are the UKRI Policy Fellowships 2026

    UK Research and Innovation opened its 2026 call on 9 June 2026, and the UKRI Policy Fellowships 2026 now offer 50 embedded fellowship positions across 26 host partners spanning UK government departments, devolved administrations, arm’s-length bodies and the What Works Network. Each fellowship runs for 18 months and places a researcher directly inside a policy team, working alongside civil servants on live evidence needs rather than producing research at arm’s length.

    The scheme sits within UKRI’s wider fellowship investment framework, which funds researcher mobility between academia and non-academic settings. Unlike a conventional secondment negotiated bilaterally between a university and a government department, the policy fellowships route is a competitive, centrally administered funding call with fixed strands, published cost ceilings and a standard exemplar agreement — details that matter as much to research offices as to the applicants themselves.

    Applications close at 16:00 on Thursday 10 September 2026, submitted through the UKRI Funding Service by the applicant’s employing research organisation.

    Funding strands, amounts and cost-sharing

    The 2026 call is organised into three funding strands, each with its own focus, eligible career stage and full economic cost (FEC) ceiling. UKRI funds 80% of the FEC; the remaining 20% is met by the fellow’s employing research organisation, consistent with the standard UKRI research grant cost-sharing model rather than a fully funded secondment.

    Strand Focus FEC ceiling Career stage
    Core Policy Fellowships Priority areas across UK and devolved government Up to £180,000 Early or mid-career
    What Works Innovation Fellowships Homelessness, policing and place, via the What Works Network Up to £220,000 All career stages
    Natural Hazards and Resilience Fellowships System resilience and preparedness for environmental risk Up to £280,000 Early or mid-career

    Host partners named against these strands include the Department for Business and Trade, the Ministry of Housing, Communities and Local Government, the Scottish Government, the Department of Health and Social Care, the UK Health Security Agency, the Ministry of Justice, the Home Office, the Department for Education, the Cabinet Office, the Environment Agency, the Centre for Homelessness Impact and the Wales Centre for Public Policy, among others. Thematic clusters span economic growth and industrial strategy, health inequalities, justice and public safety, education, housing and place, and the use of data and AI in government.

    Eligibility, key dates and how to apply

    Applicants must hold a doctorate or equivalent research experience, be based at a UKRI-eligible research organisation, and demonstrate subject-matter expertise relevant to a specific fellowship position. UKRI is explicit that career stage is not time-bound by years since doctorate; a researcher without a PhD may still qualify if they can evidence an equivalent sustained research-focused role. Researchers who have already undertaken or are currently undertaking a UKRI policy fellowship are not eligible to reapply.

    • Call opened: 9 June 2026, 09:00
    • Applicant webinar: 25 June 2026
    • Deadline: 10 September 2026, 16:00
    • Shortlisting: October to November 2026
    • Interviews: January 2027
    • Decisions: February 2027
    • Fellowship start: 1 May 2027

    Only the lead research organisation can submit an application to UKRI, though the fellowship agreement itself is negotiated between three parties: the host partner, the fellow, and the employing research organisation. Fellows must also pass any security, nationality and clearance checks the specific host requires before the placement can begin.

    What is the deadline for UKRI Policy Fellowships 2026?

    Applications for the UKRI Policy Fellowships 2026 close at 16:00 on Thursday 10 September 2026, submitted via the UKRI Funding Service. Only the applicant’s lead employing research organisation can make the submission, so institutional sign-off must be secured well before this deadline.

    Who is eligible to apply for UKRI policy fellowships?

    Eligible applicants hold a doctorate or equivalent research experience, are based at a UKRI-eligible research organisation, and meet the early or mid-career descriptor for Core Policy and Natural Hazards strands. What Works Innovation Fellowships are open to researchers at all career stages, including those without a completed doctorate.

    How many UKRI policy fellowship positions are available in 2026?

    UKRI is funding 50 fellowship positions across 26 host partners in the 2026 call, spanning UK government departments, devolved administrations, arm’s-length bodies and What Works Network members. Positions are distributed unevenly across the three funding strands and named host organisations.

    How is UKRI policy fellowship funding structured?

    UKRI funds 80% of the full economic cost of each fellowship, up to strand-specific ceilings of £180,000, £220,000 or £280,000. The employing research organisation covers the remaining 20%, matching UKRI’s standard grant cost-sharing model rather than a fully externally funded secondment.

    How research offices administer secondment agreements and reporting

    For research administrators, the operational detail sits below the headline figures. UKRI requires a formal fellowship or secondment agreement between the host partner, the fellow and the employing research organisation before a placement starts. UKRI has published an exemplar agreement, developed in consultation with UKRI Legal, central government departments and the university sector, and advises institutions to review it well ahead of submission rather than treating it as a post-award formality.

    This has direct implications for how institutions resource the administration of placement schemes:

    • Costing and 20% co-funding sign-off: Because UKRI funds only 80% of FEC, finance teams must confirm the department or faculty can cover the balance before the application is submitted, not after the award is made.
    • Compliance checks: UKRI states plainly that research office and finance teams undertake checks on hosting arrangements and financial eligibility, while ultimate responsibility for compliance remains with the applicant — a split of accountability research offices should document in their own sign-off workflow.
    • Host-specific clearance: Security and nationality checks vary by host department, so administrators cannot rely on a single institutional template; each placement’s clearance requirements need checking against the specific host’s published criteria.
    • Mentor and team roles: Early-career applicants must name a senior mentor from their employing organisation, adding a role that research offices need to track alongside the fellow and the host contact.
    • Reporting during placement: Fellows remain employed by their home institution throughout, so payroll, HR and reporting lines stay with the research organisation even while day-to-day line management sits with the host — a dual-reporting structure that research administration systems must be configured to reflect.

    This three-way agreement structure — host, fellow, employer — is the genuine administrative distinction of the UKRI scheme compared with informally negotiated academic-government exchanges, and it is the detail most coverage of the 2026 call omits in favour of headline position and funding counts.

    Implications for institutions and applicants

    Research offices supporting an applicant should treat the fellowship agreement review as a parallel workstream to the academic proposal, not a downstream task. Given the FEC ceilings scale with strand rather than individual placement complexity, institutions should also confirm early whether their standard overhead recovery models accommodate an 80/20 split embedded within a government host, rather than a conventional university-based grant.

    Applicants working with sensitive or linked administrative datasets should note that feasibility assessments — including secure data access approvals — need to be scoped against the 18-month fellowship window from the outset, since data access timelines can otherwise outrun the placement itself.

    Outlook: what happens after the September deadline

    With shortlisting running October to November 2026, interviews in January 2027 and a fellowship start date of 1 May 2027, institutions have a multi-month gap between submission and confirmed placement — a window research offices can use to finalise co-funding approvals, mentor arrangements and host-specific clearance paperwork rather than leaving them until decisions land. As UKRI continues to expand policy fellowship strands beyond their original remit, research administrators are likely to see this three-party agreement model applied to further embedded-researcher schemes, making early familiarity with the exemplar agreement a transferable skill rather than a one-off task.

  • NIH Biosketch Rules in 2026: The SciENcv Common Form Compliance Guide

    What is the NIH biosketch, and why did it just change?

    The NIH biosketch is the standardised biographical document that every senior/key person and other significant contributor must submit with an NIH grant application, so that peer reviewers and programme staff can judge whether the named personnel have the expertise, track record, and capacity to carry out the proposed work.

    Since 25 January 2026, that document has changed shape. Driven by federal research-security directives (NSPM-33) that push all federal funding agencies toward shared “Common Forms,” NIH retired the familiar single Word-based biosketch template. In its place sits the Biographical Sketch Common Form, produced exclusively through SciENcv (Science Experts Network Curriculum Vitae), the NIH-hosted researcher-profile system.

    The change is not cosmetic. It affects how contributions are documented, what identifiers are mandatory, and how compliance is checked before submission.

    The new Biographical Sketch Common Form: structure and sections

    The old biosketch was a single four-part document. The new format splits the content across two linked outputs generated together in SciENcv: the Biographical Sketch Common Form itself, and a separate NIH Biographical Sketch Supplement.

    • Biographical Sketch Common Form — identifying information, a Persistent Identifier (ORCID iD) field, professional preparation, appointments and positions, and a “Products” list.
    • NIH Biographical Sketch Supplement — Personal Statement, Honors, and Contributions to Science, all cross-referenced to the Products list rather than carrying their own citations.
    • Section D (Scholastic Performance), previously required only for Fellowship applications, has been eliminated entirely.

    The table below summarises the practical differences institutions need to build into their internal checklists.

    Feature Pre-2026 biosketch New Biographical Sketch Common Form (SciENcv)
    Production method Manually formatted Word/PDF template Generated and digitally certified inside SciENcv only
    Document structure Single document, four sections Common Form plus a separate Biosketch Supplement
    Page limit Fixed 5-page limit No overall page limit; section-level character and entry limits apply
    Citations in Personal Statement Permitted Not permitted; narrative must reference numbered items in the Products list
    Products/contributions cap Up to 5 contributions, 4 publications each Up to 5 products most closely related to the project, plus up to 5 other significant products
    Scholastic Performance (Fellowships) Required (Section D) Removed
    ORCID iD Optional/recommended Mandatory, linked to eRA Commons
    Certification Signature on submission package Digital certification required in SciENcv before the locked PDF can be downloaded

    SciENcv: how to generate a compliant biosketch

    Every senior/key person needs a My NCBI account linked to SciENcv, accessed consistently through one sign-in route — eRA Commons, ORCID, or an institutional credential — since switching methods can silently spawn duplicate profiles.

    Three linked steps matter most for research offices tracking each named investigator:

    1. Obtain and verify an ORCID iD, then link it to both the eRA Commons account and the SciENcv profile — now a mandatory field, not an optional courtesy line.
    2. Populate the Common Form sections (preparation, positions, Products) and the linked Supplement (Personal Statement, Honors, Contributions to Science), keeping product references numbered consistently across both documents.
    3. Digitally certify the biosketch in SciENcv, including the attestation of non-participation in a Malign Foreign Talent Recruitment Program, before downloading the final locked PDF.

    Because SciENcv applies formatting automatically and locks the PDF after certification, manual font and margin errors — a historically common source of NIH compliance rejections — are largely engineered out. What replaces them is a new failure mode: incomplete or unlinked identifiers, which block certification outright rather than drawing a reviewer’s note.

    Page limits, character limits, and format rules

    This is the single most misunderstood change, and it is worth stating plainly because several existing summaries online still describe the old rule as current: the traditional 5-page limit no longer applies. SciENcv does not enforce a page count on the Common Form or Supplement.

    In its place, NIH built section-level constraints directly into the SciENcv fields:

    • The Products section is capped at five items most closely related to the proposed project, plus up to five other significant products regardless of relevance to the current project.
    • The Personal Statement and Contributions to Science narratives carry character limits enforced by the SciENcv text fields rather than a page count.
    • Citations may no longer be embedded directly in the Personal Statement; instead, applicants reference the numbered Products list.
    • Template integrity rules persist from the legacy format: no deleted section headings, no inserted figures or tables, and no hyperlinks other than a link to a federal repository of the applicant’s published work (for example, My Bibliography).

    Research administrators verifying compliance should stop counting pages and instead check that every named person has a current ORCID-linked SciENcv profile, the Products list stays within the five-plus-five cap, and the PDF carries a SciENcv digital certification mark rather than a typed signature block.

    Answer-first Q&A

    What is an NIH biosketch?

    An NIH biosketch is a standardised biographical document required for every senior/key person and other significant contributor named on an NIH grant application. It summarises education, appointments, and research contributions so that reviewers can assess whether the named personnel can carry out the proposed work.

    Is an NIH biosketch the same as a CV?

    No. A biosketch is similar to a CV but far more constrained: it follows a fixed government template, limits the number of listed products, and (in the current SciENcv-generated version) must be digitally certified. A full curriculum vitae has no such structural or format restrictions.

    What does the new NIH biosketch look like?

    The new biosketch is generated entirely inside SciENcv as two linked outputs: the Biographical Sketch Common Form (identifying information, positions, Products) and the NIH Biographical Sketch Supplement (Personal Statement, Honors, Contributions to Science), both requiring digital certification before download.

    What is the difference between the NIH biosketch and the NIH Biosketch Common Form?

    “NIH biosketch” is the general term for the required biographical document; the Biographical Sketch Common Form is the specific, standardised template — shared across federal agencies under NSPM-33 alignment — that has been mandatory since 25 January 2026 and must be produced through SciENcv rather than a manually edited file.

    Transition deadlines and what research offices must verify

    The effective date is fixed: NIH Guide Notice NOT-OD-26-018 requires the Biographical Sketch Common Form and the Supplement for application due dates, and for Just-in-Time, Research Performance Progress Report, and Prior Approval submissions, on or after 25 January 2026. Confirm exactly which Common Forms a given opportunity requires against its Notice of Funding Opportunity, since transition scenarios vary by submission type.

    For research administration teams, that shifts the compliance-verification workload in three concrete ways:

    • Identity infrastructure, not just document review. Compliance now depends on whether every named person’s ORCID iD is correctly linked to eRA Commons and SciENcv — a check that must happen weeks before a deadline, not the night before submission.
    • Certification status over formatting checks. Since SciENcv locks formatting automatically, the meaningful pre-submission check is whether the PDF carries SciENcv’s digital certification, not whether margins and fonts look right.
    • Contribution narrative discipline. With citations stripped from the Personal Statement and Contributions to Science tied to a capped Products list, PIs need a clear way to describe prior contributions. Structured contributor-role taxonomies help here: CASRAI originated the CRediT contributor role taxonomy in 2014, now stewarded by NISO as ANSI/NISO Z39.104-2022. NIH does not require CRediT tags in a biosketch, but mapping a contribution against a defined CRediT role before drafting keeps “Contributions to Science” statements precise and defensible under review.

    Looking ahead: what PIs and institutions should do now

    The shift to SciENcv-generated biosketches is now in force, not pending — any PI or research office still working from a saved Word template is out of compliance. The priority list is short: confirm every senior/key person has an ORCID iD linked to eRA Commons, rebuild biosketches in SciENcv ahead of the next deadline, and update proposal-review checklists to look for SciENcv certification marks rather than page counts.

    Institutions that treat this as an identity-and-process change, not a one-off template swap, will avoid the scramble that follows when a funder mandate moves from “recommended” to “required” without warning. As other federal funders align their own forms to the same Common Form standard under NSPM-33, the SciENcv workflow described here is likely to become the baseline expectation well beyond NIH applications.

  • Retraction Watch Database Free: How to Use It for Institutional Due Diligence

    When a hiring committee, grant panel, or co-author vetting workflow needs to check a candidate’s publication record, the Retraction Watch Database is usually the first stop. Accessing the retraction watch database free of charge is now straightforward, but only if research offices know which of its three access routes to use — and where its coverage runs thin. This guide sets out a practical, step-by-step approach for institutional due diligence, plus the credibility caveats a screening checklist should not skip.

    What is the Retraction Watch database?

    The Retraction Watch Database (RWDB) is maintained by the Center for Scientific Integrity, the nonprofit behind the Retraction Watch blog founded in 2010 by science journalists Ivan Oransky and Adam Marcus. It now logs more than 65,000 retractions, corrections, and expressions of concern, up from roughly 40,000 entries at the time of its September 2023 data-sharing agreement with Crossref, which made the dataset far more widely and openly accessible.

    Retraction Watch also publishes derivative lists that get searched separately: the Retraction Watch Leaderboard (most-retracted individual authors) and country-level breakdowns used in bibliometric research. These are useful signals, but they are not substitutes for a record-level check, as the sections below explain.

    How to search the Retraction Watch database for free

    There are three free access routes, and each suits a different due-diligence task.

    Access method Best for Coverage / updates Cost and limits
    Web search form (retractiondatabase.org) Quick, single-name or single-DOI checks Live; each search returns up to 50 entries Free; since October 2024 you must fill at least one of article type, a date range, or a PMID/DOI
    Full CSV download (Crossref GitLab repository) Bulk screening of long candidate or co-investigator lists Complete dataset, refreshed periodically Free; no per-query limits
    Crossref REST API Automated checks embedded in onboarding or grant systems Updated on working days from publisher data Free; standard Crossref API rate limits apply

    For a single name or one paper’s DOI, the web form is fastest. For anything resembling a batch check — a full hiring shortlist, an entire grant consortium, or an author list on a multi-author manuscript — the CSV download or the API is the correct tool, because the web interface’s per-search filter requirement makes open-ended browsing impractical by design.

    Using the database for hiring, grant, and co-author due diligence

    Research offices increasingly build RWDB checks into standard screening, alongside conflict-of-interest disclosures and authorship verification. A workable process looks like this:

    • Before a hiring or tenure decision, batch-check the candidate’s DOI or PMID list against the CSV download rather than the web form, which is not built for unfiltered browsing.
    • For grant panels, check every named co-investigator’s publication list, not only the principal investigator’s — retraction risk is frequently concentrated in co-authored papers rather than sole-authored ones.
    • For co-author vetting ahead of a manuscript submission, search prospective collaborators by name and affiliation, and treat a “Correction” or “Expression of Concern” entry as a prompt for further reading, not an automatic disqualifier.
    • Record the query date and parameters used: RWDB entries are added and revised continuously, so a clean result today is not a permanent clearance.
    • Cross-reference any hit against PubMed and the publisher’s own notice before acting on it, given documented metadata discrepancies between databases.

    Common questions, answered

    Is there a Retraction Watch database?

    Yes. The Retraction Watch Database is maintained by the Center for Scientific Integrity and hosted at retractiondatabase.org. It logs more than 65,000 retractions, corrections, and expressions of concern, and since September 2023 has been distributed publicly through a data agreement with Crossref.

    Use the free web form at retractiondatabase.org, filtering by article type, date range, or a PMID/DOI — required since October 2024 to manage server load. For bulk or unrestricted searching, download the complete dataset as a free CSV from Crossref’s GitLab repository instead.

    How do I check if a specific article has been retracted?

    Search the article’s DOI or PMID directly in the RWDB, or check the publisher’s own page for a retraction notice. Tools such as Zotero and the Crossref REST API also flag retracted status automatically when a DOI is queried or a reference is added to a library.

    Is Retraction Watch data comprehensive for corrections and expressions of concern?

    No. Retraction Watch states its database is the most complete source specifically for retractions; coverage of corrections and expressions of concern is skewed toward items linked to existing retractions or its own reporting, so due-diligence teams should treat those two categories as indicative rather than exhaustive.

    Limits, credibility, and what the leaderboard does (and doesn’t) tell you

    The RWDB’s own user guide is explicit about its boundaries: expressions of concern and corrections are entered “as they relate to existing retractions, blog posts, or high-profile studies,” not comprehensively, so any counts of those two record types drawn from the database will be skewed and should not be read as population-representative.

    Is Retraction Watch credible for institutional due diligence? The evidence points to yes, with caveats. The Center for Scientific Integrity’s dataset has been independently examined in the academic literature — a 2025 study in Accountability in Research compared RWD metadata accuracy against PubMed and Web of Science and found it a strong, though not flawless, source. Its integration into Crossref’s scholarly infrastructure since 2023 adds a layer of institutional stewardship beyond a single newsroom, and reference tools such as Zotero rely on it to flag retracted citations automatically.

    The Retraction Watch Leaderboard — a running list of the most-retracted individual researchers, topped for years by anaesthesiologist Yoshitaka Fujii with more than 180 retractions — and country-level breakdowns used in bibliometric studies are genuinely useful for spotting patterns. But leaderboard rank reflects investigative attention and reporting history as much as underlying prevalence, and cross-country comparisons need population and output normalisation that the raw retraction watch by country counts do not themselves provide. Neither should replace a DOI-level check on the specific individual or paper under review.

    Implications for research offices

    The database’s growth — from roughly 40,000 entries at the time of the Crossref agreement to more than 65,000 now — reflects both rising retraction volume and improved detection, not necessarily declining research quality alone. For research administration teams, the practical implication is to treat RWDB screening as a routine, documented step in research administration workflows, sitting alongside authorship and contributorship checks rather than as an ad hoc search performed only when a concern is already raised.

    As programmatic access matures through the Crossref API, expect RWDB checks to become embedded directly into hiring, grants, and manuscript systems, much as authorship verification already is. Institutions that build this into a documented, repeatable checklist — rather than a one-off Google search — will be better placed to defend their due-diligence decisions if a retraction surfaces after the fact.

  • MRC and BBSRC Open Access Policy: How UKRI’s Research Councils Diverge

    Grant administrators handling awards that straddle more than one UK Research and Innovation (UKRI) council quickly discover that “one policy” does not mean “one set of instructions.” The MRC open access policy and the Biotechnology and Biological Sciences Research Council (BBSRC) open access policy both sit inside UKRI’s single overarching open access framework, yet the Medical Research Council (MRC) and BBSRC apply distinct additional expectations around Europe PMC deposit, embargo language and preprint citation. For institutions administering multi-council grants, those gaps — not the shared UKRI baseline — are where compliance actually breaks down.

    The shared UKRI foundation

    Since 1 April 2022, UKRI has run a single open access policy covering peer-reviewed research articles, conference papers and reviews acknowledging funding from any of its seven councils, including MRC and BBSRC. From 1 January 2024 the policy extended to monographs, book chapters and edited collections, requiring open access within 12 months of publication.

    For journal articles, the UKRI policy sets out two routes to compliance:

    • Route 1 (Gold): the publisher’s version of record is made immediately open access, typically under a CC BY licence.
    • Route 2 (Green): the author’s accepted manuscript is deposited in a repository and made immediately available at the point of publication.

    Both MRC and BBSRC researchers must comply with this baseline. The divergence begins with what each council layers on top of it.

    How MRC and BBSRC diverge in practice

    MRC’s own policy page states plainly that funded researchers are “expected to comply” with the UKRI policy and must ensure a copy of every in-scope publication is deposited in Europe PubMed Central (Europe PMC) at the time of final publication — a requirement MRC treats as mandatory, with a named contact ([email protected]) for compliance queries.

    BBSRC’s published guidance, by contrast, frames Europe PMC archiving as something researchers are “strongly encouraged” to do rather than an enforced condition, and separately states that BBSRC-funded results must be made freely available “no later than six months from the formal date of publication” — language that sits alongside, rather than fully aligned with, UKRI’s 2022 immediate-access requirement. In practice this means MRC administrators treat Europe PMC deposit as a hard compliance gate, while BBSRC administrators are working from softer, less current wording.

    Requirement MRC BBSRC
    Base policy UKRI open access policy UKRI open access policy
    Europe PMC deposit Required, tied to funding terms and conditions Strongly encouraged, not stated as mandatory
    Stated access timeline Immediate, per UKRI policy Guidance still references a 6-month freely-available window
    Preprints in applications Accepted, subject to MRC preprints policy Accepted; must carry a DOI and be under 5 years old
    Block grant / OA funding route UKRI block grant plus institutional strategic funding UKRI block grant plus a dedicated BBSRC Open Access Grant for strategically funded institutes

    The block grant distinction matters for multi-council awards: a BBSRC-funded institute receiving strategic funding is eligible for a separate BBSRC Open Access Grant on top of the standard UKRI block grant allocation, whereas MRC funding does not carry an equivalent parallel grant line. Administrators reconciling publication costs across a joint MRC–BBSRC award therefore need to identify which funding pot a given article’s costs should be drawn from, rather than assuming a single shared allocation.

    Common questions from grant administrators

    What is the MRC open access policy?

    The MRC open access policy requires researchers funded by the Medical Research Council to comply with the overarching UKRI open access policy and to deposit a copy of every in-scope publication in Europe PMC at the time of final publication, whether via the gold or green route.

    Does BBSRC require Europe PMC deposit?

    BBSRC’s guidance encourages researchers to archive published articles in Europe PMC but does not state this as a mandatory condition in the way MRC does, making it a softer compliance expectation that administrators should still track for biomedical-adjacent outputs.

    What is the difference between MRC and BBSRC open access requirements?

    Both follow the same UKRI baseline, but MRC treats Europe PMC deposit as compulsory while BBSRC treats it as encouraged, and BBSRC’s own guidance still references a six-month access window that predates UKRI’s 2022 immediate-access requirement.

    Will REF 2029 use the same open access policy as UKRI?

    The UK’s four higher education funding bodies have signalled that REF 2029 open access requirements will move closer to the UKRI framework, including extending expectations to long-form outputs, but REF policy is set separately from UKRI’s council-level rules and administrators should not assume identical scope or timing.

    REF 2029 open access alignment

    The Research Excellence Framework is administered by the four UK higher education funding bodies — Research England, the Scottish Funding Council, the Higher Education Funding Council for Wales and the Department for the Economy in Northern Ireland — not by UKRI’s research councils directly. For REF 2021, the open access policy applied to journal articles and conference proceedings, with a deposit window measured from acceptance rather than publication.

    For REF 2029, the funding bodies have indicated closer alignment with UKRI’s current policy, including bringing long-form outputs such as monographs into scope in a manner consistent with UKRI’s January 2024 monograph requirement. For a multi-council award spanning MRC and BBSRC funding, this means outputs already compliant with the UKRI open access route are well placed for REF eligibility, but administrators should confirm the specific REF 2029 rules once published rather than relying on UKRI compliance as an automatic proxy.

    Implications for multi-council award administrators

    The practical risk on a joint MRC–BBSRC grant is not non-compliance with the UKRI baseline — most institutions have that workflow embedded — but under-tracking the council-specific layer on top of it. Three things follow from the comparison above:

    1. Treat Europe PMC deposit as mandatory for any output acknowledging MRC funding, and as strongly recommended (verify locally) for BBSRC-only outputs.
    2. Do not assume a single open access funding pot covers a joint award; check whether the receiving institute holds a BBSRC Open Access Grant in addition to its UKRI block grant.
    3. Flag REF 2029 scope changes as a live item rather than a fixed rule, since final funding-body guidance may extend beyond the current UKRI monograph policy.

    Institutions supporting research administration across multiple UKRI councils benefit from building compliance checklists that separate “UKRI-wide” requirements from “council-specific” additions, rather than treating open access as a single monolithic policy. As REF 2029 guidance solidifies and UKRI continues its open access policy review, the gap between MRC’s stricter Europe PMC language and BBSRC’s older embargo wording is the clearest signal that “UKRI open access policy” is a floor, not a uniform standard — and that administrators verifying terminology such as gold, green and embargo routes should consult a maintained research administration dictionary alongside each council’s primary source.

  • Registry of Open Access Repository Mandates and Policies: A ROARMAP Guide for Research Administrators

    When a research office needs to check whether a funder requires immediate deposit or permits a twelve-month embargo, guesswork is not good enough. The registry of open access repository mandates and policies — known by its acronym ROARMAP — exists precisely to remove that guesswork. Maintained by the School of Electronics and Computer Science at the University of Southampton, it is a searchable, international catalogue of the open access mandates that universities, research institutions and funders have adopted, and it remains one of the few places where those policies can be compared side by side rather than tracked down one funder website at a time.

    This matters more in 2026 than it did a decade ago. Funder mandates have multiplied, cOAlition S members continue to refine Plan S implementation, and — as a June 2026 German constitutional ruling shows — even settled mandates can be challenged in court. Research administrators, library staff and compliance officers need a single reference point that tracks all of it. ROARMAP is that reference point.

    What ROARMAP catalogues, and why it matters

    ROARMAP began life in 2003 as the Institutional Archives Registry, built by the EPrints team at the University of Southampton. It was renamed the Registry of Open Access Repositories Mandatory Archiving Policies in 2006, then adjusted again, settling on its current name — Registry of Open Access Repository Mandates and Policies — around 2014. Throughout those renamings, its purpose stayed constant: track every publicly documented policy that requires or encourages researchers to make peer-reviewed outputs openly accessible, usually by depositing a copy in a repository.

    ROARMAP has a companion registry, ROAR (the Registry of Open Access Repositories), which indexes the repositories themselves rather than the policies that govern them. The distinction trips people up regularly, so it is worth setting out clearly alongside a third commonly confused resource, OpenDOAR.

    Registry What it indexes Typical use case
    ROARMAP Open access mandates and policies from institutions and funders Checking what a funder or institution requires
    ROAR Open access repositories themselves — location, size, growth Finding where a repository is hosted
    OpenDOAR Curated, vetted directory of repositories and their technical metadata Selecting a compliant repository to deposit into

    Entries in ROARMAP are not uniform in strength. Some record a simple recommendation to self-archive; others are mandatory policies where compliance is tied to continued grant funding — the sanction that gives a mandate real teeth. As of the last widely cited published count, ROARMAP had catalogued policies from more than 520 universities and over 75 research funders worldwide, a figure that has continued to grow as more institutions formalise their open access requirements.

    How cOAlition S members’ policies are catalogued

    cOAlition S is the group of research funders — including national funders, charitable foundations and the European Commission — that came together in 2018 to implement Plan S, the requirement that publicly funded research be made immediately open access without embargo. Because cOAlition S members are funders rather than repository operators, their individual mandates are exactly the kind of entry ROARMAP was built to hold.

    Each cOAlition S member’s policy is entered as a discrete record, so an administrator can look up, for example, what a specific national research council requires on licensing (typically CC BY), acceptable routes to compliance (Gold, Green with a zero-embargo repository deposit, or a transformative agreement), and how the policy interacts with the funder’s own compliance-monitoring tools, such as the Journal Checker Tool. Because ROARMAP predates Plan S by more than a decade, it also preserves the pre-2018 policy text for many of these funders, which is useful when institutions need to establish exactly when a requirement changed.

    This is a genuine information gain over simply reading each funder’s website individually: ROARMAP lets an administrator filter by funder type, country and adoption date, surfacing patterns — such as clusters of European funders tightening embargo terms in the same policy cycle — that are invisible from any single funder’s own page.

    Using the registry to compare institutional and funder mandates

    For day-to-day compliance work, ROARMAP is used less as a browsing tool and more as a lookup and benchmarking tool. A typical workflow for a research administrator looks like this:

    • Search by country or institution name to confirm whether a specific university has a formal mandate, and since when.
    • Filter by policymaker type — funder versus institution — to separate overlapping obligations on a single researcher.
    • Check the deposit timing and permitted embargo period recorded against each policy.
    • Note the required manuscript version — preprint, accepted manuscript or version of record.
    • Compare licensing requirements (commonly CC BY) where the policy specifies one.
    • Benchmark a draft institutional policy against comparable peer institutions before it goes to committee.

    This benchmarking use case is one of ROARMAP’s most practical applications. Rather than drafting an institutional open access policy from a blank page, a policy officer can pull several comparable universities’ mandates from the registry, line up their deposit windows and enforcement mechanisms, and use that comparison to justify the strength of a proposed new policy to institutional leadership.

    What is an open access repository?

    An open access repository is a freely accessible digital archive where researchers self-archive peer-reviewed articles, preprints or accepted manuscripts so readers can access them without a paywall. Universities run institutional repositories; funders and disciplines run subject-based ones. ROARMAP catalogues the policies requiring deposit — not the repositories themselves.

    How does OpenDOAR differ from ROARMAP?

    OpenDOAR is a curated directory listing vetted open access repositories and their technical characteristics, while ROARMAP lists the mandates and policies that require deposit into those repositories. Administrators typically use OpenDOAR to identify a compliant repository, then check ROARMAP to confirm whether deposit is compulsory and on what terms.

    What is self-archiving, and how do ROARMAP-listed policies define it?

    Self-archiving — the “Green” route to open access — means an author deposits a manuscript into a repository alongside, or instead of, publishing openly with a journal. Policies catalogued in ROARMAP typically specify the deposit timing, permitted embargo length, and which manuscript version satisfies the mandate.

    What are the drawbacks of relying on open access mandates?

    Mandates catalogued in registries such as ROARMAP vary widely in enforcement: some merely encourage deposit while others tie compliance to grant payment. Weak or unmonitored policies show low actual deposit rates, embargo terms conflict across funders, and legal challenges — as seen in Germany in 2026 — can unsettle even long-established mandates.

    What the changing legal landscape means for research administrators

    ROARMAP’s value is not static, and 2026 has already supplied a reminder of why. In June, Germany’s Federal Constitutional Court struck down a state-level bylaw at the University of Konstanz that would have compelled researchers to exercise their statutory secondary-publication right — ruling that regulating copyright through employment or institutional statute conflicted with the federal government’s exclusive legislative competence over copyright law. The University of Konstanz noted afterwards that the ruling changed little in practice, because the great majority of its researchers already deposit voluntarily. But the case is a useful illustration for administrators elsewhere: a mandate’s formal status, its legal basis and its actual compliance rate can diverge, and a registry entry captures only the first of those three.

    That gap between formal mandate and practical uptake is exactly why registries such as ROARMAP function as compliance infrastructure rather than mere reference material. Institutions revising their own open access policy — whether to align with cOAlition S requirements, respond to a national research assessment exercise, or pre-empt a legal challenge — need a documented, dated record of what comparable institutions and funders actually require, not an assumption based on the last policy a colleague happened to read. For a wider view of how these obligations sit alongside contributorship and compliance frameworks more broadly, CASRAI’s research administration resources and dictionary of research terms provide further grounding.

    As funder policies continue to tighten and jurisdictions test the legal limits of mandated deposit, expect ROARMAP’s role to shift from a static archive towards a living reference that research offices consult routinely, alongside compliance checkers and repository directories, whenever a grant agreement, tenure case or institutional policy review depends on knowing exactly what an open access mandate actually requires.